Mark B. McClellan
Known title: DirectorCIK: 0001567006
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings. Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.
Transaction History
| CI | ▲ Buy | Grant | 782 | $0 | 4/22/2026 | View on chart |
| ALHC | ▲ Buy | Grant | 13,096 | $0 | 3/13/2026 | View on chart |
| CI | ▲ Buy | Grant | 638 | $0 | 4/23/2025 | View on chart |
| ALHC | ▲ Buy | Grant | 12,258 | $0 | 3/13/2025 | View on chart |
| CI | ▲ Buy | Grant | 539 | $0 | 4/24/2024 | View on chart |
| ALHC | ▲ Buy | Grant | 30,000 | $0 | 3/13/2024 | View on chart |
| CI | ▲ Buy | Grant | 765 | $0 | 4/26/2023 | View on chart |
| ALHC | ▲ Buy | Grant | 21,802 | $0 | 3/8/2023 | View on chart |
| CI | ▲ Buy | Grant | 757 | $0 | 4/27/2022 | View on chart |
| ALHC | ▲ Buy | Grant | 16,556 | $0 | 3/8/2022 | View on chart |
| CI | ▲ Buy | Grant | 199 | $0 | 2/28/2022 | View on chart |
| CI | ▲ Buy | Grant | 247 | $0 | 11/30/2021 | View on chart |
| ALHC | ▼ Sell | Open Market | 7,500 | $151K | 11/23/2021 | View on chart |
| CI | ▲ Buy | Grant | 224 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cigna Focuses on Data-Driven Care and Valuation Metrics
Recent coverage highlights Cigna's strategic shift toward data-driven care through its Health Sense initiative, positioning it as a key differentiator in the healthcare sector. Analysts are also examining the stock's valuation, noting a forward P/E that suggests value despite ongoing earnings risks. With the stock trading near its 52-week high, these developments provide context for its current market position relative to peers like UnitedHealth.
Cigna Focuses on Data-Driven Care and Valuation Metrics. Recent coverage highlights Cigna's strategic shift toward data-driven care through its Health Sense initiative, positioning it as a key differentiator in the healthcare sector. Analysts are also examining the stock's valuation, noting a forward P/E that suggests value despite ongoing earnings risks. With the stock trading near its 52-week high, these developments provide context for its current market position relative to peers like UnitedHealth.